Kardium Inc.
- Industry
- Medical Device
- Founded Year
- 2007
- Headquarters
- Vancouver, Canada
- Employee Count
- 400
Key People
- Kevin Chaplin - CEO
- Dr. Robert Atkinson - Founder & CTO
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a strong background in medical technology.
Kardium's leadership includes individuals with significant experience in the MedTech industry, contributing to the company's innovative approach and strategic direction.
- Clinical Need
-
Aspect: Very Strong
Summary: Atrial fibrillation affects over 59 million people worldwide, indicating a substantial clinical need.
With a significant global patient population, there is a pressing need for advanced and efficient treatment options for atrial fibrillation, which Kardium aims to address with its Globe Pulsed Field System.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The electrophysiology market is highly competitive, with major players like Boston Scientific and Medtronic.
The electrophysiology market features strong competition from well-established firms, making it challenging for new entrants to gain significant market share.
- Technical Challenge
-
Aspect: Complex
Summary: Developing integrated systems for atrial fibrillation treatment involves significant technical complexities.
Creating a comprehensive system that combines multiple functionalities into a single catheter requires overcoming substantial technical hurdles, which can affect the product's time-to-market and overall development expenses.
- Patent
-
Aspect: Strong
Summary: Kardium holds multiple patents related to its Globe Pulsed Field System.
Holding multiple patents provides Kardium with a competitive edge by protecting its innovative technologies and potentially preventing competitors from developing similar products.
- Financing
-
Aspect: Well-funded
Summary: Kardium has secured significant funding from reputable investors.
With substantial financial backing from investors like Teralys Capital, Lumira Ventures, and BDC, Kardium is well-positioned to continue its product development and market expansion initiatives.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The Globe Pulsed Field System is undergoing pivotal clinical trials.
The completion and success of pivotal clinical trials are essential steps toward obtaining regulatory approvals, which will enable Kardium to commercialize its product and address the clinical need for atrial fibrillation treatment.
Opportunity Rollup
- Odds of Success
- 3.25
- Peak Market Share
- 3.8
- Segment CAGR
- 15.2%
- Market Segment
- Electrophysiology Devices
- Market Sub Segment
- Ablation Catheters
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.19 |
| 2 | 0.57 |
| 3 | 1.33 |
| 4 | 2.66 |
| 5 | 3.80 |
Key Takeaway
Kardium's innovative approach addresses a significant clinical need, but success depends on navigating a competitive landscape and achieving regulatory milestones.